BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Hypertriglyceridemia Market – Forecast to 2030,’ thoroughly examines the Hypertriglyceridemia industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Marfan Syndrome Market – Forecast to 2030,’ thoroughly examines the Marfan Syndrome industry to provide essential data & information for the targeted readers.

Olympus Corporation announced the launch of VISERA ELITE III, its newest surgical visualization platform that addresses the needs of healthcare professionals for endoscopic procedures across multiple medical disciplines.

POINT Biopharma Global Inc., a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, announced the pricing of its public offering of 13,900,000 shares of Common Stock at a public offering price of $9.00 per share.

The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics Limited announced the launch of Radiopharm Ventures, LLC, a joint venture company created to develop novel radiopharmaceutical therapeutic products for cancer.

The virology market size was USD 2.06 billion in 2021 and is expected to register a revenue CAGR of 5.0% over the forecast period, according to the latest report by Reports and Data.

GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the poster presentation of further clinical validation data for PurIST℠, a novel RNA-expression test, in collaboration with Tempus.

MediciNova, Inc. today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia.

AIDS Healthcare Foundation (AHF), which has been sharply critical of Los Angeles County leadership in its handling of monkeypox, is now expanding its call on government and public health officials everywhere to greatly scale up vaccine rollout and prevention messaging nationwide.

Edgewise Therapeutics, Inc. announced the pricing of its upsized underwritten public offering of 11,627,907 shares of its common stock at a price to the public of $10.32 per share.